cet

AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer

PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER, WITH BIOMARKER-DRIVEN…

3 weeks ago

Fagron increases share capital through exercise subscription rights

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 June 2025 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron…

2 months ago

Equasens: availability of AGM preparatory materials

Villers-lès-Nancy, 6 June 2025 - 6:00 p.m. (CET) PRESS RELEASE ANNUAL ORDINARY GENERAL MEETING MEETING NOTICE ON-LINE AVAILABILITY OF MEETING…

2 months ago

Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of 4.00

Press release Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of…

2 months ago